Pseudomonas aeruginosa (PA) eradication is crucial in cystic fibrosis (CF) management. At our center, the success rate was 21.6%, prompting a revised eradication protocol to evaluate a new regimen.
Methods:
Cystic fibrosis patients with first-time PA detection were included. Nonmucoid PA cases received oral ciprofloxacin (3 weeks) and inhaled tobramycin (1 month). For mucoid PA or failed eradication, ciprofloxacin (3 weeks) and extended nebulized therapy (3 months, alternating tobramycin/colistin) were used. Intravenous antibiotics were given to unwell patients.
Results:
Among 109 CF patients (median age: 6 years), 79 (72.5%) achieved successful eradication. Oral ciprofloxacin and tobramycin inhalation were used in 66 patients (60.6%), extended nebulized therapy in 26 (23.8%), and intravenous antibiotics in 17(15.6%).
Conclusion:
The revised protocol achieved a high PA eradication rate in CF patients. Adapting treatment regimens based on PA characteristics and patient condition can optimize outcomes and improve CF management.
SagelSDGibsonRLEmersonJ, et al. Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J Pediatr. 2009;154:183-188.
2.
BallmannMRabschPvon der HardtH.Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Thorax. 1998;53(9):732-737.
3.
EmersonJRosenfeldMMcNamaraSRamseyBGibsonRL.Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002;34(2):91-100
4.
PamukcuABushABuchdahlR.Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatr Pulmonol. 1995;19(1):10-15
5.
KosorokMRZengLWestSE, et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol. 2001;32(4):277-287.
6.
NixonGMArmstrongDSCarzinoR, et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr. 2001;138(5):699-704.
7.
MogayzelPJJrNaureckasETRobinsonKA, et al. Cystic Fibrosis Foundation pulmonary guideline. Pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection. Ann Am Thorac Soc. 2014;11(10):1640-1650.
8.
JohansenHKHøibyN.Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark. Thorax. 1992;47(2):109-111.
9.
SpagnoloAMSartiniMMariaLC.Pseudomonas aeruginosa in the healthcare facility setting. Rev Med Microbiol. 2021;32(3):169-175.
10.
MaselliJHSontagMKNorrisJMMacKenzieTWagenerJSAccursoFJ.Risk factors for initial acquisition of Pseudomonas aeruginosa in children with cystic fibrosis identified by newborn screening. Pediatr Pulmonol. 2003;35(4):257-262.
11.
RatjenFComesGPaulK, et al. Effect of continuous antistaphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis. Pediatr Pulmonol. 2001;31(1):13-16.
12.
LiZKosorokMRFarrellPM, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA. 2005;293:581.
13.
Silva FilhoLVFerreira FdeAReisFJ, et al. Pseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatment. J Bras Pneumol. 2013;39(4):495-512
14.
MunckABonacorsiSMariani-KurkdjianP, et al. Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization. Pediatr Pulmonol. 2001;32(4):288-292.
15.
MursalogluHHAkınCYılmaz YeğitC, et al. Comparison of intravenous and non-intravenous antibiotic regimens in eradication of P. aeruginosa and MRSA in cystic fibrosis. Pediatr Pulmonol. 2021;56(12):3745-3751
16.
LeeTWBrownleeKGConwaySPDentonMLittlewoodJM.Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros. 2003;2(1):29-34.
17.
Royal Brompton and Harefield, NHS Foundation Trust. Clinical guidelines: Care of children with cystic fibrosis. 7th ed. London: Royal Brompton & Harefield NHS Foundation Trust; 2017.
18.
GrahamBLSteenbruggenIMillerMR, et al. Standardization of spirometry 2019 Update. An official American thoracic society and European respiratory society technical statement. Am J Respir Crit Care Med. 2019;200(8):e70-e88.
19.
KonstanMWMorganWJButlerSM, et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr. 2007;151(02):134139-134139.
20.
SomayajiRLamJCSuretteMG, et al. Long-term clinical outcomes of “Prairie Epidemic Strain” Pseudomonas aeruginosa infection in adults with cystic fibrosis. Thorax. 2017;72(4):333-339.
21.
RatjenFMunckAKhoPAngyalosiG, Elite Study Group. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax. 2010;65:286-291.
22.
SmythARBellSCBojcinS, et al. European cystic fibrosis society standards of care: best practice guidelines. J Cyst Fibros. 2014;13(Suppl 1):S23-42
23.
ProesmansMVermeulenFBoulangerLVerhaegenJDe BoeckK.Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis. J Cyst Fibros. 2013;12(1):29-34.
24.
HewerSCLSmythARBrownM, et al. Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (torpedo-cf): a randomised controlled trial. Lancet Respir Med. 2020;8(10):975-986.
25.
BlanchardACHortonEStanojevicSTaylorLWatersVRatjenF.Effectiveness of a stepwise Pseudomonas aeruginosa eradication protocol in children with cystic fibrosis. J Cyst Fibros. 2017;16(3):395-400
26.
YohannesAMWillgossTGFatoyeFADipMDWebbK.Relationship between anxiety, depression, and quality of life in adult patients with cystic fibrosis. Respir Care. 2012;57(4):550-556.
27.
WangALeeMKellerA, et al. Sex differences in outcomes of people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor. J Cyst Fibros. 2023;23(1):91-98.
28.
NickJAChaconCSBrayshawSJ, et al. Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis. Am J Respir Crit Care Med. 2010;182:614-626.
29.
VermaNBushABuchdahlR.Is there still a gender gap in cystic fibrosis. Chest. 2005;128(4):2824-2834.
30.
CasarediIGShawMWatersVSeetoRBlanchardACRatjenF.Impact of antibiotic eradication therapy of Pseudomonas aeruginosa on long-term lung function in cystic fibrosis. J Cyst Fibros2023;22(1):98-102.
31.
KeremECoreyMSteinRGoldRLevisonH.Risk factors for Pseudomonas aeruginosa colonization in cystic fibrosis patients. Pediatr Infect Dis J. 1990;9(7):494-498.
32.
SchnellAHoberHKaiserN, et al. Elexacaftor—Tezacaftor—Ivacaftor treatment improves systemic infection parameters and Pseudomonas aeruginosa colonization rate in patients with cystic fibrosis a monocentric observational study. Heliyon. 2023;9(5):e15756.
33.
DurfeySLPipavathSLiA, et al. Combining ivacaftor and intensive antibiotics achieves limited clearance of cystic fibrosis infections. Mbio. 2021;12:e0314821.
